Recent Updates
Recently added Catalysts
SNDL Negative Sentiment Score: 30/100

SNDL Inc. Condensed Consolidated Interim Financial Statements For the three and nine months ended

Key Takeaway: SNDL Inc. reported its condensed consolidated interim financial statements for the third quarter of 2023, revealing a net loss of CAD 21.8 million. The company's accumulated deficit has risen to CAD 1.178 billion. Despite an increase in revenue from CAD 660.6 million, costs and operational inefficiencies have contributed to continued losses. Additionally, the company has seen fluctuations in its biological assets and significant impairments impacting overall financial health.

Market Sentiment Analysis

CONCERNS & RISKS

  • Significant net loss of CAD 21.8 million for the third quarter.
  • Accumulated deficit increased to CAD 1.178 billion.
  • Operational losses continued, with loss from operations of CAD 16.4 million.

Full Press Release Details

Condensed Consolidated Interim Financial Statements
For the three and nine months ended September 30, 2023
(Unaudited expressed in thousands of Canadian dollars)
Condensed Consolidated Interim Statement of Financial Position
(Unaudited - expressed in thousands of Canadian dollars)
As at Note September 30, 2023 December 31, 2022
Assets
Current assets
Cash and cash equivalents 201,983 279,586
Restricted cash 19,661 19,338
Marketable securities 6 265 21,926
Accounts receivable 25,505 22,636
Biological assets 7 562 3,477
Inventory 8 142,550 127,782
Prepaid expenses and deposits 17,814 10,110
Investments 14 3,400 6,552
Assets held for sale 3(a),9 8,391 6,375
Net investment in subleases 12 3,603 3,701
423,734 501,483
Non-current assets
Long-term deposits 9,720 8,584
Right of use assets 10 133,792 134,154
Property, plant and equipment 11 176,144 143,409
Net investment in subleases 12 18,262 19,618
Intangible assets 13 73,776 74,885
Investments 14 29,058 90,702
Equity-accounted investees 15 550,523 519,255
Goodwill 3(a) 148,282 67,260
Total assets 1,563,291 1,559,350
Liabilities
Current liabilities
Accounts payable and accrued liabilities 57,230 48,153
Lease liabilities 17 33,809 30,206
Derivative warrants 16 6,800 11,002
97,839 89,361
Non-current liabilities
Lease liabilities 17 137,201 139,625
Other liabilities 6,860 2,709
Total liabilities 241,900 231,695
Shareholders' equity
Share capital 18(b) 2,366,775 2,292,810
Warrants 2,260 2,260
Contributed surplus 76,912 68,961
Contingent consideration 2,279 2,279
Accumulated deficit (1,178,063 ) (1,091,999 )
Accumulated other comprehensive income 31,306 32,188
Total shareholders' equity 1,301,469 1,306,499
Non-controlling interest 19,922 21,156
Total liabilities and shareholders' equity 1,563,291 1,559,350
Commitments (note 27)
Subsequent events (notes 18 and 28)
See accompanying notes to the condensed consolidated interim financial statements.
Condensed Consolidated Interim Statement of Loss and Comprehensive Loss
(Unaudited - expressed in thousands of Canadian dollars, except per share amounts)
Three months ended September 30 Nine months ended September 30
Note 2023 (1) 2022 2023 (1) 2022
Gross revenue (1) 20 249,796 235,144 696,118 482,828
Excise taxes (1) 12,201 4,644 35,562 11,036
Net revenue 237,595 230,500 660,556 471,792
Cost of sales (1) 8 180,375 179,093 503,444 367,710
Inventory impairment and obsolescence 8 9,126 (2,307 ) 22,594 3,545
Gross margin before fair value adjustments 48,094 53,714 134,518 100,537
Change in fair value of biological assets (1,819 ) (1,899 ) (6,767 ) 1,403
Change in fair value realized through inventory 2,330 (1,506 ) 5,328 (5,133 )
Gross margin 48,605 50,309 133,079 96,807
Interest and fee revenue 21 3,445 4,312 11,077 10,750
Investment loss 21 (29 ) (5,513 ) (9,218 ) (58,296 )
Share of profit (loss) of equity-accounted investees 15 6,581 9,176 15,161 (24,711 )
General and administrative 48,235 45,014 149,535 95,989
Sales and marketing 3,271 1,935 10,761 6,178
Research and development 57 1,503 217 1,988
Depreciation and amortization 10,11,13 15,545 9,783 45,456 19,322
Share-based compensation 19 5,373 2,069 11,475 6,711
Restructuring costs 708 6,286 (882 )
Asset impairment 11,13 1,783 86,522 4,248 88,372
Loss from operations (16,370 ) (88,542 ) (77,879 ) (193,128 )
Transaction costs (226 ) (417 ) (2,439 ) 1,040
Finance costs, net 22 (2,142 ) (8,409 ) (9,773 ) (34,853 )
Change in estimate of fair value of derivative warrants 16 (2,840 ) (8,500 ) 4,202 6,856
Foreign exchange gain (loss) (235 ) 91 (429 ) 102
Gain (loss) on disposition of assets (14 ) 6 (275 ) 408
Loss before income tax (21,827 ) (105,771 ) (86,593 ) (219,575 )
Income tax recovery 6,927 8,718
Net loss from continuing operations (21,827 ) (98,844 ) (86,593 ) (210,857 )
Net loss from discontinued operations 4 (4,535 )
Net loss (21,827 ) (98,844 ) (91,128 ) (210,857 )
Equity-accounted investees - share of other comprehensive income (loss) 15 11,124 23,194 (882 ) 29,188
Comprehensive loss (10,703 ) (75,650 ) (92,010 ) (181,669 )
Net loss from continuing operations attributable to:
Owners of the Company (21,784 ) (98,108 ) (85,337 ) (209,313 )
Non-controlling interest (43 ) (736 ) (1,256 ) (1,544 )
(21,827 ) (98,844 ) (86,593 ) (210,857 )
Net loss attributable to:
Owners of the Company (21,784 ) (98,108 ) (89,872 ) (209,313 )
Non-controlling interest (43 ) (736 ) (1,256 ) (1,544 )
(21,827 ) (98,844 ) (91,128 ) (210,857 )
Comprehensive loss attributable to:
Owners of the Company (10,660 ) (74,914 ) (90,754 ) (180,125 )
Non-controlling interest (43 ) (736 ) (1,256 ) (1,544 )
(10,703 ) (75,650 ) (92,010 ) (181,669 )
Net loss per common share attributable to owners of the Company
Basic and diluted 24 $ (0.08 ) $ (0.41 ) $ (0.35 ) $ (0.92 )
(1) Recast - refer to note 20.
See accompanying notes to the condensed consolidated interim financial statements.
Condensed Consolidated Interim Statement of Changes in Shareholders' Equity
(Unaudited - expressed in thousands of Canadian dollars)
Note Share capital Warrants Contributed surplus Contingent consideration Accumulated deficit Accumulated other comprehensive income Non-controlling interest Total
Balance at December 31, 2022 2,292,810 2,260 68,961 2,279 (1,091,999 ) 32,188 21,156 1,327,655
Net loss (89,872 ) (1,256 ) (91,128 )
Other comprehensive loss (882 ) (882 )
Share repurchases 18(b) (5,344 ) 3,808 (1,536 )
Share issuances by subsidiaries 25 26 51
Acquisition 3(a) 83,953 602 84,555
Shares acquired and cancelled 18(b) (6,615 ) (6,615 )
Share-based compensation 19 9,295 9,295
Employee awards exercised 18(b) 1,971 (1,971 )
Distribution declared by subsidiaries (4 ) (4 )
Balance at September 30, 2023 2,366,775 2,260 76,912 2,279 (1,178,063 ) 31,306 19,922 1,321,391
Balance at June 30, 2023 2,365,845 2,260 73,636 2,279 (1,156,279 ) 20,182 19,965 1,327,888
Net loss (21,784 ) (43 ) (21,827 )
Other comprehensive income 11,124 11,124
Acquisition 602 602
Share-based compensation 19 3,604 3,604
Employee awards exercised 18(b) 930 (930 )
Balance at September 30, 2023 2,366,775 2,260 76,912 2,279 (1,178,063 ) 31,306 19,922 1,321,391
Condensed Consolidated Interim Statement of Changes in Shareholders' Equity
(Unaudited - expressed in thousands of Canadian dollars)
Note Share capital Warrants Contributed surplus Contingent consideration Accumulated deficit Accumulated other comprehensive income Non- controlling interest Total equity
Balance at December 31, 2021 2,035,704 8,092 60,734 2,279 (785,112 ) 7,607 229 1,329,533
Net loss (209,313 ) (1,544 ) (210,857 )
Other comprehensive income 29,188 29,188
Share issuances 2,870 2,870
Share repurchases (16,532 ) 10,383 (6,149 )
Share issuances by subsidiaries 57 35 92
Acquisition 287,129 58,250 345,379
Warrants expired (5,832 ) 5,832
Share-based compensation 8,530 114 8,644
Employee awards exercised 1,747 (1,747 )
Distribution declared by subsidiaries (11 ) (11 )
Balance at September 30, 2022 2,310,918 2,260 73,406 2,279 (984,042 ) 36,795 57,073 1,498,689
Balance at June 30, 2022 2,322,273 8,092 65,043 2,279 (893,200 ) 13,601 57,801 1,575,889
Net loss (98,108 ) (736 ) (98,844 )
Other comprehensive income 23,194 23,194
Share repurchases (11,362 ) 7,266 (4,096 )
Warrants expired (5,832 ) 5,832
Share-based compensation 2,538 19 2,557
Employee awards exercised 7 (7 )
Distribution declared by subsidiaries (11 ) (11 )
Balance at September 30, 2022 2,310,918 2,260 73,406 2,279 (984,042 ) 36,795 57,073 1,498,689
See accompanying notes to the condensed consolidated interim financial statements.
Condensed Consolidated Interim Statement of Cash Flows
(Unaudited - expressed in thousands of Canadian dollars)
Three months ended September 30 Nine months ended September 30
Note 2023 2022 2023 2022
Cash provided by (used in):
Operating activities
Net loss for the period (21,827 ) (98,844 ) (91,128 ) (210,857 )
Adjustments for:
Income tax recovery (6,927 ) (8,718 )
Interest and fee revenue 21 (3,445 ) (4,312 ) (11,077 ) (10,750 )
Change in fair value of biological assets 1,819 1,899 6,767 (1,403 )
Share-based compensation 19 5,373 2,069 11,475 6,711
Depreciation and amortization 10,11,13 16,602 11,294 49,535 24,271
Loss (gain) on disposition of assets 14 (6 ) 275 (408 )
Inventory obsolescence 8 9,126 (2,307 ) 22,594 3,545
Finance costs 22 2,142 8,409 9,773 34,853
Change in estimate of fair value of derivative warrants 16 2,840 8,500 (4,202 ) (6,856 )
Unrealized foreign exchange loss (gain) 68 (75 ) 44 (40 )
Asset impairment 1,783 86,522 4,248 88,372
Share of (profit) loss of equity-accounted investees 15 (6,581 ) (9,176 ) (15,161 ) 24,711
Realized loss on settlement of marketable securities 6,21 46,082 138,874
Unrealized loss on marketable securities 6,21 (46,053 ) 5,513 (129,656 ) 58,685
Additions to marketable securities (3,500 )
Proceeds from settlement of marketable securities 6 3,241 6,704
Income distributions from equity-accounted investees 976 1,661
Interest received 3,325 3,874 10,245 9,673
Change in non-cash working capital 23 13,033 1,163 (43,722 ) (45,271 )
Net cash provided by (used in) operating activities from continuing operations 27,542 8,572 (34,412 ) (35,321 )
Net cash provided by operating activities from discontinued operations 4 4,314
Net cash provided by (used in) operating activities 27,542 8,572 (30,098 ) (35,321 )
Investing activities
Additions to property, plant and equipment 11 (3,042 ) (2,119 ) (5,683 ) (6,654 )
Additions to intangible assets 13 (32 ) (88 ) (55 )
Additions to investments 195 (60,676 ) (507 ) (74,770 )
Additions to equity-accounted investees 15 (8,072 ) (16,989 ) (102,272 )
Proceeds from disposal of property, plant and equipment 1,150 3 1,287 4,003
Acquisitions, net of cash acquired 3 3,695 (31,149 )
Change in non-cash working capital 23 730 (754 ) 1,857 (495 )
Net cash used in investing activities from continuing operations (999 ) (71,618 ) (16,428 ) (211,392 )
Net cash used in investing activities from discontinued operations 4
Net cash used in investing activities (999 ) (71,618 ) (16,428 ) (211,392 )
Financing activities
Change in restricted cash (205 ) 70 (323 ) 7,677
Payments on lease liabilities, net (9,793 ) (9,127 ) (29,400 ) (18,751 )
Repurchase of common shares, net of costs 18(b) (4,096 ) (1,536 ) (6,149 )
Repayment of long-term debt (10,000 )
Change in non-cash working capital 23 (17 ) 4,996 182 7,112
Net cash used in financing activities from continuing operations (10,015 ) (8,157 ) (31,077 ) (20,111 )
Net cash used in financing activities from discontinued operations 4
Net cash used in financing activities (10,015 ) (8,157 ) (31,077 ) (20,111 )
Change in cash and cash equivalents 16,528 (71,203 ) (77,603 ) (266,824 )
Cash and cash equivalents, beginning of period 185,455 362,630 279,586 558,251
Cash and cash equivalents, end of period 201,983 291,427 201,983 291,427
See accompanying notes to the condensed consolidated interim financial statements.
Notes to the Condensed Consolidated Interim Financial Statements
For the three and nine months ended September 30, 2023
(Unaudited, expressed in thousands of Canadian dollars, except where otherwise noted)
1.Description of business
SNDL Inc. ( SNDL or the Company ) was incorporated under the Business Corporations Act (Alberta) on August 19, 2006. On July 25, 2022, the Company's shareholders approved a special resolution amending the articles of SNDL to change the name of the Company from Sundial Growers Inc. to SNDL Inc. .
The Company's head office is located at 300, 919 11th Avenue SW, Calgary, Alberta, Canada.
The principal activities of the Company are the retailing of wines, beers and spirits, the operation and support of corporate-owned and franchise retail cannabis stores in Canadian jurisdictions where the private sale of recreational cannabis is permitted, the manufacturing of cannabis products providing proprietary cannabis processing services, the production, distribution and sale of cannabis domestically and for export pursuant to the Cannabis Act (Canada) (the Cannabis Act ), and the deployment of capital to investment opportunities. The Cannabis Act regulates the production, distribution, and possession of cannabis for both medical and adult recreational access in Canada. The Company also owns approximately 63% of Nova Cannabis Inc. ( Nova ) (TSX: NOVC), whose principal activities are the retail sale of cannabis.
SNDL and its subsidiaries operate solely in Canada. Through its joint venture, SunStream Bancorp Inc. ( SunStream ) (note 15), the Company provides growth capital that pursues indirect investment and financial services opportunities in the cannabis sector, as well as other investment opportunities. The Company also makes strategic portfolio investments in debt and equity securities.
The Company's common shares trade on the Nasdaq Capital Market under the ticker symbol SNDL .
2.Basis of presentation
Statement of compliance
The condensed consolidated interim financial statements ( financial statements ) have been prepared in accordance with International Accounting Standard 34 Interim Financial Reporting as issued by the International Accounting Standards Board and interpretations of the International Financial Reporting Interpretations Committee. These financial statements were prepared using the same accounting policies and methods as those disclosed in the annual consolidated financial statements for the year ended December 31, 2022. These financial statements should be read in conjunction with the annual consolidated financial statements for the Company for the year ended December 31, 2022.
These financial statements were approved and authorized for issue by the Board of Directors ( Board ) on November 10, 2023.
3.Business acquisitions
On January 17, 2023, the Company acquired all of the issued and outstanding common shares of The Valens Company Inc. ( Valens ), other than those owned by SNDL and its subsidiaries, by way of a statutory plan of arrangement (the Valens Transaction ). The Valens Transaction consideration was comprised of (i) the assumption of Valens' $60 million non-revolving term loan facility from its then existing lender, (ii) an aggregate 27.6 million SNDL common shares valued at $84.0 million based on the fair value of each common share of the Company on the closing date (0.3334 of a SNDL common share for each Valens common share), and (iii) contingent consideration valued at $0.6 million representing the fair value of Valens stock options.
Valens is a manufacturer of cannabis products providing proprietary cannabis processing services, in addition to product development, manufacturing, and commercialization of cannabis consumer packaged goods. Valens products are formulated for the medical, health and wellness, and recreational consumer segments.
Notes to the Condensed Consolidated Interim Financial Statements
For the three and nine months ended September 30, 2023
(Unaudited, expressed in thousands of Canadian dollars, except where otherwise noted)
The Company has engaged independent valuation experts to assist in determining the fair value of certain assets acquired and liabilities assumed and related deferred income tax impacts. The purchase price allocation is not final as the Company is continuing to obtain and verify information required to determine the fair value of certain assets and liabilities and the amount of deferred income taxes, if any, arising on their recognition.
Due to the inherent complexity associated with valuations and the timing of the acquisition, the amounts below are provisional and subject to adjustment.
The fair value of consideration paid was as follows:
Provisional Adjustments Provisional
Valens loan facility 61,512 61,512
Issuance of common shares 83,953 83,953
Contingent consideration 602 602
145,465 602 146,067
The preliminary fair value of the assets and liabilities acquired was as follows:
Provisional Adjustments Provisional
Cash 3,615 3,615
Accounts receivable 21,361 21,361
Investments 876 876
Prepaid expenses and deposits 4,980 4,980
Inventory 14,140 14,140
Assets held for sale 6,330 6,330
Right of use assets 2,882 2,882
Property, plant and equipment 63,030 (10,938 ) 52,092
Intangible assets 2,285 (785 ) 1,500
Goodwill 68,697 12,325 81,022
Accounts payable and accrued liabilities (34,185 ) (34,185 )
Contractual obligation (5,339 ) (5,339 )
Lease liabilities (3,207 ) (3,207 )
145,465 602 146,067
As new information is obtained within one year of the date of acquisition, about facts and circumstances that existed at the date of acquisition, identifies adjustments to the above amounts, the accounting for the acquisition will be revised.
Valens subsidiary Green Roads, Inc. ( Green Roads ) was sold and has been classified as held for sale and discontinued operations (note 4).
The financial statements incorporate the operations of Valens commencing January 18, 2023. During the period January 18, 2023 to September 30, 2023 the Company recorded gross revenues of $63.1 million and net loss of $37.9 million from the Valens operations. Had the Valens Transaction closed on January 1, 2023, management estimates that for the period January 1, 2023, to January 17, 2023, revenue would have increased by $4.2 million and net loss would have increased by $2.1 million. In determining these amounts, management assumes the fair values on the date of acquisition would have been the same as if the acquisition had occurred on January 1, 2023.
The Company incurred costs related to the Valens Transaction of $2.8 million which have been included in transaction costs.
On February 7, 2023, the Company acquired the right, title and interest in (i) five Superette retail locations within Toronto and Ottawa; (ii) the intellectual property rights related to the Superette brand; and (iii) the shares of Superette Ontario (collectively, the Superette Transaction ).
Notes to the Condensed Consolidated Interim Financial Statements
For the three and nine months ended September 30, 2023
(Unaudited, expressed in thousands of Canadian dollars, except where otherwise noted)
The Superette acquisition consideration was comprised of the extinguishment of the Company's promissory note.
The fair value of consideration paid was as follows:
Extinguishment of promissory note 2,625
2,625
The fair value of the assets and liabilities acquired was as follows:
Cash 80
Accounts receivable 30
Prepaid expenses and deposits 141
Inventory 371
Right of use assets 1,129
Property, plant and equipment 2,077
Accounts payable and accrued liabilities (74 )
Lease liabilities (1,129 )
2,625
The financial statements incorporate the operations of Superette commencing February 8, 2023. During the period February 8, 2023 to September 30, 2023 the Company recorded gross revenues of $2.8 million and net loss of $1.2 million from the Superette operations. Had the Superette Transaction closed on January 1, 2023, management estimates that for the period January 1, 2023, to February 7, 2023, revenue would have increased by $0.5 million and net loss would have increased by $0.1 million. In determining these amounts, management assumes the fair values on the date of acquisition would have been the same as if the acquisition had occurred on January 1, 2023.
The Company incurred costs related to the Superette Transaction of $0.7 million which have been included in transaction costs.
4.Discontinued operations
The Green Roads operations acquired as part of the Valens acquisition were classified as held for sale and discontinued operations as the carrying amount of the disposal group was expected to be recovered through a sale transaction rather than through continued use.
Green Roads filed for bankruptcy on March 6, 2023. A successful bid of US$3.1 million was accepted and the sale was approved at a court hearing on May 10, 2023. The disposition of Green Roads closed on May 31, 2023 and a loss on disposition of $2.3 million was recorded.
The consolidated statement of loss and comprehensive loss and consolidated statement of cash flows have been presented to show the discontinued operations separately from continuing operations.
Notes to the Condensed Consolidated Interim Financial Statements
For the three and nine months ended September 30, 2023
(Unaudited, expressed in thousands of Canadian dollars, except where otherwise noted)
Results of discontinued operations
Three months ended September 30 Nine months ended September 30
2023 2022 2023 2022
Net revenue 7,510
Cost of sales 3,841
Gross margin 3,669
General and administrative 3,639
Sales and marketing 1,817
Depreciation and amortization 450
Loss from operations (2,237 )
Finance costs (16 )
Loss on disposition (2,282 )
Net loss (4,535 )
5.Segment information
The Company's reportable segments are organized by business line and are comprised of four reportable segments: liquor retail, cannabis retail, cannabis operations, and investments.
Liquor retail includes the sale of wines, beers and spirits through owned liquor stores. Cannabis retail includes the private sale of adult-use cannabis through owned and franchise retail cannabis stores. Cannabis operations include the cultivation, distribution and sale of cannabis for the adult-use and medical markets domestically and for export, and providing proprietary cannabis processing services, in addition to product development, manufacturing, and commercialization of cannabis consumer packaged goods. Investments include the deployment of capital to investment opportunities. Certain overhead expenses not directly attributable to any operating segment are reported as Corporate .
Notes to the Condensed Consolidated Interim Financial Statements
For the three and nine months ended September 30, 2023
(Unaudited, expressed in thousands of Canadian dollars, except where otherwise noted)
Liquor Retail Cannabis Retail (1) Cannabis Operations (2) Investments (3) Corporate Total
As at September 30, 2023
Total assets 321,598 209,684 299,489 712,859 19,661 1,563,291
Nine months ended September 30, 2023
Net revenue (4) 419,402 214,828 61,027 (34,701 ) 660,556
Gross margin 98,890 53,645 (19,456 ) 133,079
Interest and fee revenue 75 10,723 279 11,077
Investment (loss) income (611 ) (8,607 ) (9,218 )
Share of profit of equity-accounted investees 15,161 15,161
Depreciation and amortization 27,943 11,391 2,750 3,372 45,456
Earnings (loss) from operations 14,528 5,768 (46,792 ) 16,963 (68,346 ) (77,879 )
Income (loss) before income tax 10,200 3,230 (46,725 ) 13,287 (66,585 ) (86,593 )
Three months ended September 30, 2023
Net revenue (4) 151,801 75,539 20,954 (10,699 ) 237,595
Gross margin 37,263 20,046 (8,704 ) 48,605
Interest and fee revenue 17 3,326 102 3,445
Investment (loss) income (114 ) 85 (29 )
Share of profit of equity-accounted investees 6,581 6,581
Depreciation and amortization 9,436 4,340 954 815 15,545
Earnings (loss) from operations 8,257 3,481 (13,971 ) 9,886 (24,023 ) (16,370 )
Income (loss) before income tax 6,449 2,753 (13,774 ) 9,834 (27,089 ) (21,827 )
(1)Cannabis retail includes the operations of Superette for the period February 8, 2023 to September 30, 2023.
(2)Cannabis operations includes the operations of Valens for the period January 18, 2023 to September 30, 2023.
(3)Total assets include cash and cash equivalents.
(4)Recast - refer to note 20.
Liquor Retail (1) Cannabis Retail (1) Cannabis Operations Investments (2) Corporate Total
As at December 31, 2022
Total assets 351,338 200,393 163,130 825,151 19,338 1,559,350
Nine months ended September 30, 2022
Net revenue 302,435 137,208 32,149 471,792
Gross margin 69,380 31,684 (4,257 ) 96,807
Interest and fee revenue 10,750 10,750
Investment loss (58,296 ) (58,296 )
Share of loss of equity-accounted investees (24,711 ) (24,711 )
Depreciation and amortization 5,722 6,041 9 7,550 19,322
Earnings (loss) from operations 24,517 (82,512 ) (16,930 ) (71,732 ) (46,471 ) (193,128 )
Income (loss) before income tax 19,042 (84,681 ) (16,686 ) (98,721 ) (38,529 ) (219,575 )
Three months ended September 30, 2022
Net revenue 152,488 66,202 11,810 230,500
Gross margin 35,568 14,494 247 50,309
Interest and fee revenue 4,312 4,312
Investment loss (5,513 ) (5,513 )
Share of profit of equity-accounted investees 9,176 9,176
Depreciation and amortization 2,923 3,199 3,661 9,783
Earnings (loss) from operations 13,302 (83,708 ) (5,673 ) 7,936 (20,399 ) (88,542 )
Income (loss) before income tax 10,736 (84,848 ) (5,686 ) 3,252 (29,225 ) (105,771 )
(1)Liquor retail includes operations of Alcanna Inc. ( Alcanna ) retail stores for the period March 31, 2022 to September 30, 2022, and cannabis retail includes operations of Nova retail stores for the period March 31, 2022 to September 30, 2022.
(2)Total assets include cash and cash equivalents.
Notes to the Condensed Consolidated Interim Financial Statements
For the three and nine months ended September 30, 2023
(Unaudited, expressed in thousands of Canadian dollars, except where otherwise noted)
Geographical disclosure
As at September 30, 2023, the Company had non-current assets related to investment credit operations in the United States of $550.5 million (December 31, 2022 $519.3 million). For the three and nine months ended September 30, 2023, share of profit of equity-accounted investees related to operations in the United States was a gain of $6.6 million and $15.2 million, respectively (three and nine months ended September 30, 2022 gain of $9.2 million and a loss of $24.7 million, respectively). All other non-current assets relate to operations in Canada and revenues from external customers relate to operations in Canada.
6.Marketable securities
As at September 30, 2023 December 31, 2022
Balance, beginning of year 21,926 83,724
Acquisition (note 3(a)) 876
Additions 3,755
Dispositions (13,319 )
Change in fair value recognized in profit or loss (9,218 ) (65,553 )
Balance, end of period 265 21,926
The Company's biological assets consist of cannabis plants in various stages of vegetation, including plants which have not been harvested. The change in carrying value of biological assets is as follows:
As at September 30, 2023 December 31, 2022
Balance, beginning of year 3,477 4,410
Increase in biological assets due to capitalized costs 19,867 27,749
Acquisition 909
Net change in fair value of biological assets (6,767 ) (1,309 )
Transferred to inventory upon harvest (16,015 ) (28,282 )
Balance, end of period 562 3,477
Biological assets are valued in accordance with IAS 41 and are presented at their fair value less costs to sell up to the point of harvest. This is determined using a model which estimates the expected harvest yield in grams for plants currently being cultivated, and then adjusts that amount for the expected selling price less costs to produce and sell per gram.
The fair value measurements for biological assets have been categorized as Level 3 fair values based on the inputs to the valuation technique used. The Company's method of accounting for biological assets attributes value accretion on a straight-line basis throughout the life of the biological asset from initial cloning to the point of harvest.
Management believes the most significant unobservable inputs and their impact on fair value of biological assets are as follows:

Frequently Asked Questions

What are the total assets as of September 30, 2023?

Total assets amount to 1,563,291 thousand Canadian dollars.

How much is the net loss for the three months ended September 30, 2023?

The net loss for this period is 21,827 thousand Canadian dollars.

What was the gross margin for the nine months ended September 30, 2023?

The gross margin is reported as 133,079 thousand Canadian dollars.

How much cash and cash equivalents were reported on September 30, 2023?

Cash and cash equivalents totaled 201,983 thousand Canadian dollars.

What is the shareholders' equity as of September 30, 2023?

Shareholders' equity stands at 1,301,469 thousand Canadian dollars.

Last updated: Nov 13, 2023